- id: 101
  name: "Effectiveness - Protection"
  description: "Clinical/real-world protection; does it prevent illness/death?"
- id: 102
  name: "Effectiveness - Effectiveness against variants"
  description: "Performance vs. variants (e.g., Delta/Omicron/H5N1)"
- id: 103
  name: "Effectiveness - Duration of immunity"
  description: "How long protection lasts; waning over time"
- id: 104
  name: "Effectiveness - Breakthrough cases"
  description: "Infections/hospitalizations despite vaccination"
- id: 105
  name: "Effectiveness - Effectiveness by group"
  description: "Subgroups: age, comorbidity, pregnancy, etc."
- id: 106
  name: "Effectiveness - Epidemiology & statistics"
  description: "Population rates, % vaccinated/unvaccinated outcomes, big-N stats"

- id: 201
  name: "Safety - Minor side effects"
  description: "Typical short-lived effects (fever, soreness, fatigue)"
- id: 202
  name: "Safety - Serious adverse effects"
  description: "Severe outcomes (myocarditis, stroke, death, severe disability)"
- id: 203
  name: "Safety - Long-term concerns"
  description: "Potential long-term risks; unknown future harms"
- id: 204
  name: "Safety - Safety among specific groups"
  description: "Risk in subgroups (children, elderly, pregnancy, immunocompromised)"
- id: 205
  name: "Safety - Comparisons with other vaccine types"
  description: "Safety compared across platforms/types"
- id: 206
  name: "Safety - Deliberate or planned harms"
  description: "Alleged intentional harm, malice, population control"
- id: 207
  name: "Safety - Unknown side effects"
  description: "Unspecified, vague, or alluded harms without detail"
- id: 208
  name: "Safety - Adverse event counts & signals"
  description: "Databases, large counts, ‘X died after…’, signal claims"

- id: 301
  name: "Ethics - Informed consent and transparency"
  description: "Disclosure, consent, truthful communication"
- id: 302
  name: "Ethics - Research and testing"
  description: "Study design, adequacy of trials, methodology"
- id: 303
  name: "Ethics - Autonomy"
  description: "Mandates, freedom to choose/refuse"
- id: 304
  name: "Ethics - Justice"
  description: "Fairness, access, burden distribution"
- id: 305
  name: "Ethics - Misinformation & public discourse"
  description: "Propaganda, censorship, media/online discourse"

- id: 401
  name: "Governance - Regulatory oversight and approvals"
  description: "FDA/EMA/WHO oversight, approvals, surveillance"
- id: 402
  name: "Governance - Manufacturing and distribution strategies"
  description: "Scale-up, supply chains, rollout decisions"
- id: 403
  name: "Governance - Approval processes and emergency use"
  description: "EUA/conditional approvals, processes"
- id: 404
  name: "Governance - Funding & program decisions"
  description: "Funding cuts/contracts/cancellations; who funds/defunds"
- id: 405
  name: "Governance - Leadership & qualifications"
  description: "Who’s in charge, credentials, suitability of decision-makers"
- id: 406
  name: "Governance - Commercial practices & IP"
  description: "Patents, royalties, pricing, tariffs, middlemen"
